newsfilter
← Earnings
Earnings Releases·

AchieveRx — Third Quarter 2026 Earnings Summary

  • **Financial Results:** Cash and marketable securities rose to $201.5 million as of September 30, 2026, from $187.3 million in June 2026; total operating expenses increased to $20.5 million for the quarter (vs. $14.7 million in 2025), while net loss narrowed to $12.1 million for the quarter (vs. $14.4 million in 2025) despite a $97.0 million loss for the nine months (vs. $40.0 million in 2025).
  • **Regulatory Outlook:** The NDA resubmission remains on track for Q4 2026, with potential FDA approval anticipated by Q2 2027 and a U.S. commercial launch to follow if approved.
  • **Strategic Positioning:** The company rebranded to AchieveRx (ticker "QUIT") and transitioned finished drug product manufacturing to U.S.-based Adare Pharma Solutions, supported by a completed Phase 2 e-cigarette study and Breakthrough Therapy designation for vaping cessation.
  • **Capital Allocation:** Management prioritizes disciplined capital allocation to support the NDA resubmission and launch readiness, citing a strong balance sheet driven by proceeds from warrant exercises.
Company
ACHIEVE LIFE SCIENCES INC
Sector
Healthcare
Industry
Biotechnology